[go: up one dir, main page]

WO2025193930A1 - Polythérapie par inhibiteur de wee1 - Google Patents

Polythérapie par inhibiteur de wee1

Info

Publication number
WO2025193930A1
WO2025193930A1 PCT/US2025/019738 US2025019738W WO2025193930A1 WO 2025193930 A1 WO2025193930 A1 WO 2025193930A1 US 2025019738 W US2025019738 W US 2025019738W WO 2025193930 A1 WO2025193930 A1 WO 2025193930A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
antibody
seq
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2025/019738
Other languages
English (en)
Inventor
Jianhui Ma
Xiao Guo
Catherine Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zeno Management Inc
Original Assignee
Zeno Management Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeno Management Inc filed Critical Zeno Management Inc
Publication of WO2025193930A1 publication Critical patent/WO2025193930A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • the present application relates to the fields of chemistry 7 , biochemistry 7 and medicine. More particularly, disclosed herein are combination therapies, and methods of treating diseases and/or conditions with a combination therapy described herein.
  • Maytansine and its derivatives maytansinoids are highly cytotoxic drugs. Maytansine was first isolated from east African shrub Maytenus serrata and shown to be 100- to 1000-fold more cytotoxic than conventional cancer chemotherapeutic agents like methotrexate, daunorubicin, doxorubicin, and vincristine. However, due to the narrow therapeutic window and high systemic toxicity 7 of maytansine, it is not an oncological chemotherapeutic agent when used alone and has been clinically banned from direct use in human therapy.
  • ADCs Antibody-drug conjugates
  • FDA U.S. Food and Drug Administration
  • mirvetuximab soravtansine- gynx brand name Elahere
  • DM4 maytansinoid conjugate
  • Some embodiments described herein relate to the use of a combination of Compound (A), or a pharmaceutically acceptable salt thereof, and (i) a maytansinoid, or a pharmaceutically acceptable salt thereof; or (ii) an antibody-drug conjugate comprising a maytansinoid, or a pharmaceutically acceptable salt thereof, for treating a cancer in a subject.
  • Compound (A) or a pharmaceutically acceptable salt thereof, and (i) a maytansinoid, or a pharmaceutically acceptable salt thereof; or (ii) an antibody-drug conjugate comprising a maytansinoid, or a pharmaceutically acceptable salt thereof, for treating a cancer in a subject.
  • FIG. 1A shows 2D heatmaps of in vitro synergy between Compound (A) and DM4 in OVCAR3 and OV-90 cancer cells.
  • FIG. IB illustrates protein biomarker changes in response to Compound (A) monotherapy, DM4 monotherapy and a combination of Compound (A) and DM4 in OVCAR3 cells in cultures in vitro.
  • FIG. 1C shows 2D heatmaps of in vitro synergy’ between Compound (A) and mirvetuximab soravtansine in OVCAR3 and OV-90 cancer cells.
  • FIG. 1A shows 2D heatmaps of in vitro synergy between Compound (A) and mirvetuximab soravtansine in OVCAR3 and OV-90 cancer cells.
  • ID illustrates protein biomarker changes in response to Compound (A) monotherapy, mirvetuximab soravtansine monotherapy and a combination of Compound (A) and mirvetuximab soravtansine in OVCAR3 cells in cultures in vitro.
  • FIG. 2A is a panel of graphs showing the percentage of cells with pHH3-positive staining in cell cycle, which are indicative of mitotic arrest, when OVCAR3 cancer cells were treated with DMSO (vehicle), Compound (A) monotherapy, DM4 or mirvetuximab soravtansine monotherapy, or the combination of Compound (A) + DM4 or Compound (A) + mirvetuximab soravtansine.
  • FIGS. 2B and 2C are bar graphs showing cell cycle analyses by flow cytometry with indicated markers as shown in FIG. 2A, when OVCAR3 cancer cells were treated with Compound (A) monotherapy, DM4 (FIG.
  • FIG. 2B or mirvetuximab soravtansine (FIG. 2C) monotherapy, or the combination of Compound (A) + DM4 (FIG. 2B) or Compound (A) + mirvetuximab soravtansine (FIG. 2C).
  • FIG. 3 A is a panel of images showing OVCAR3 cells with pHH3 (white), a -tubulin (light grey), and DAPI (dark grey) immunostaining, when OVCAR3 cancer cells were treated with DMSO (vehicle), Compound (A) monotherapy, mirvetuximab soravtansine monotherapy, or the combination of Compound (A) + mirvetuximab soravtansine.
  • FIG. 3B is a corresponding bar graph to FIG. 3A, depicting the percentage of cells with pHH3-positive staining.
  • FIG. 3C is a panel of representative images showing mitotic phenotypes of OVCAR3 cells.
  • FIG. 3D is a corresponding bar graph to FIG. 3C showing the percentage of cells with mitotic defects vs. the percentage of cells w ith normal mitosis, w hen OVCAR3 cancer cells w ere treated as described above for FIG. 3A.
  • FIG. 4A shows tumor volume measurements over a course of 25 days when mice inoculated with OV-90 high-grade serous ovarian cancer/carcinoma (HGSOC) tumor cells were treated with vehicle (negative control), Compound (A) monotherapy, mirvetuximab soravtansine monotherapy, and the combination of Compound (A) + mirvetuximab soravtansine.
  • FIG. 4B shows individual tumor volume changes on day 25 when mice inoculated with OV-90 cells were treated as described above for FIG. 4A.
  • FIG. 4C show s the body weight changes of the mice subject to the treatment regimens of FIG. 4A
  • an “immunoconjugale” is a conjugate comprising an immunological substance and a drug moiety that are joined together by a linker.
  • an immunoconjugate is prepared by reacting the immunological substance with a conjugate as defined herein.
  • An “antibody-drug conjugate” (ADC) is one class of immunoconjugate whereby the immunological substance is an antibody or an antigen-binding fragment thereof.
  • an “antibody” is a protein made by the immune system, or a synthetic or engineered variant thereof, that binds to specific sites on cells or tissues.
  • the term “antibody” herein is used in the broadest sense and encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multi-specific antibodies (e.g., bispecific antibodies), chimeric antibodies, nanobodies, and antigen-binding fragments so long as they exhibit the desired antigenbinding activity.
  • Monoclonal antibodies are a type of synthetic antibody. In cancer treatment, monoclonal antibodies may kill cancer cells directly, they may block development of tumor blood vessels, and/or they may help the immune system kill cancer cells.
  • Humanized antibodies are antibodies from non-human species whose protein sequences have been modified to increase their similarity to antibody variants produced naturally in humans.
  • a murine monoclonal antibody. 4D5. directed against the extracellular domain of HER2 and a potent inhibitor of growth of human breast cancer cells overexpressing HER2 in vitro and in xenograft models, was humanized by inserting the complementary determining regions of 4D5 into the framework of a consensus human IgGl.
  • the resulting recombinant humanized anti-HER2 mAb was trastuzumab.
  • An antibody typically is composed of two heavy chains and two light chains; and the heavy chain and the light chain typically each contain three complementarity-determining regions (CDRs) immunoglobulin (Ig) hypervariable domains that determine specific antibody binding.
  • CDRs complementarity-determining regions
  • Ig immunoglobulin
  • an “antigen-binding fragment” refers to a molecule other than an intact antibody that comprises a portion of an intact antibody that binds the antigen to which the intact antibody binds.
  • antibody fragments include but are not limited to Fv, Fab, Fab', Fab'-SH, F(ab’)2. diabodies, linear antibodies, single-chain antibody molecules (e.g.. scFv), and single-domain antibodies.
  • Maytansinoid refers to an analog or a derivative (e.g. , synthetic analog or derivative) of maytansine having a general structure of: , which is the structure of maytansine having modifications, such as adding substituted or unsubstituted alkyls or alkenyls, alcohols (R- OH), thiol (R-SH), ether (R-O-R’), thioether (R-S-R’), and/or disulfide groups at * in the foregoing structural formula. In some embodiments, these functional groups are introduced to facilitate covalent attachment to an antibody or an antigen-fragment thereof.
  • Nonlimiting examples of maytansinoids include DM1, S-methyl DM1 or DMl-SMe. DM4, S- methyl DM4 or DM4-SMe, DM3, DM3-SMe (see, e.g., U.S. Patent No. 7,276,497).
  • salt refers to a salt of a compound that does not cause significant irritation to an organism to which it is administered and does not abrogate the biological activity and properties of the compound.
  • the salt is an acid addition salt of the compound.
  • Pharmaceutical salts can be obtained by reacting a compound with inorganic acids such as hydrohalic acid (e.g., hydrochloric acid or hydrobromic acid), a sulfuric acid, a nitric acid and a phosphoric acid (such as 2,3-dihydroxypropyl dihydrogen phosphate).
  • Pharmaceutical salts can also be obtained by reacting a compound with an organic acid such as aliphatic or aromatic carboxylic or sulfonic acids, for example formic, acetic, succinic, lactic, malic, tartaric, citric, ascorbic, nicotinic, methanesulfonic, ethanesulfonic, p-toluensulfonic, trifluoroacetic, benzoic, salicylic, 2-oxopentanedioic or naphthalenesulfonic acid.
  • an organic acid such as aliphatic or aromatic carboxylic or sulfonic acids
  • Pharmaceutical salts can also be obtained by reacting a compound with a base to form a salt such as an ammonium salt, an alkali metal salt, such as a sodium, a potassium or a lithium salt, an alkaline earth metal salt, such as a calcium or a magnesium salt, a salt of a carbonate, a salt of a bicarbonate, a salt of organic bases such as dicyclohexylamine, N- methyl-D-glucamine, tris(hydroxymethyl)methylamine, C1-C7 alkylamine, cyclohexylamine, triethanolamine, ethylenediamine and salts with amino acids such as arginine and lysine.
  • a salt such as an ammonium salt, an alkali metal salt, such as a sodium, a potassium or a lithium salt, an alkaline earth metal salt, such as a calcium or a magnesium salt, a salt of a carbonate, a salt of a bicarbonate, a salt of organic bases such as
  • each chemical element as represented in a compound structure may include any isotope of said element.
  • a hydrogen atom may be explicitly disclosed or understood to be present in the compound.
  • the hydrogen atom can be any isotope of hydrogen, including but not limited to hydrogen-1 (protium) and hydrogen-2 (deuterium).
  • reference herein to a compound encompasses all potential isotopic forms unless the context clearly dictates otherwise.
  • One embodiment relates to the use of a combination of Compound (A) as defined above, or a pharmaceutically acceptable salt thereof, and an antibody-drug conjugate comprising a maytansinoid, or a pharmaceutically acceptable salt thereof, for treating a cancer in a subject.
  • One embodiment relates to the use of a combination of Compound (A) as defined above, or a pharmaceutically acceptable salt thereof, and an antibody-drug conjugate comprising DM4 or DM4-SMe maytansinoid (see below for structure), or a pharmaceutically acceptable salt of any of the foregoing, for treating a cancer in a subject.
  • Yet another aspect of this disclosure relates to a combination of Compound (A), or a pharmaceutically acceptable salt thereof, and (i) a maytansinoid, or a pharmaceutically acceptable salt thereof; or (ii) an antibody-drug conjugate comprising a maytansinoid, or a pharmaceutically acceptable salt thereof, for use in treating a cancer.
  • One embodiment relates to a combination of Compound (A), or a pharmaceutically acceptable salt thereof, and an antibody-drug conjugate comprising a maytansinoid, or a pharmaceutically acceptable salt thereof, for use in treating a cancer.
  • One embodiment relates to a combination of Compound (A), or a pharmaceutically acceptable salt thereof, and an antibody-drug conjugate comprising DM4 or DM4-SMe maytansinoid (see below for structure) or a pharmaceutically acceptable salt of any of the foregoing, for use in treating a cancer.
  • the maytansinoid in the uses and methods of the present disclosure is represented by the following structural formula: or a pharmaceutically acceptable salt thereof, wherein Y is -(CH2)2SH (DM1), -(CH 2 )2SHMe (DMl-SMe), -(CH 2 )2CHCH 3 SH (DM3), -(CH 2 )2CHCH 3 SMe (DM3- SMe), -(CH 2 ) 2 C(CH 3 ) 2 SH (DM4) or -(CH 2 ) 2 C(CH 3 ) 2 SMe (DM4-SMe).
  • Y is -(CH 2 )2C(CH 3 ) 2 SH (DM4).
  • Y is -(CH 2 )2C(CH 3 ) 2 SMe (DM4-SMe).
  • the antibody-drug conjugate comprising a maytansinoid is represented by the following structural formula: or a pharmaceutically acceptable salt thereof, wherein: Ab is an antibody or an antigen-binding fragment thereof; and n represents an average number of maytansinoid compounds conjugated to a single Ab and is in a range of about 1 to about 10. In one embodiment, n is in a range of about 3 to about 4.
  • One further aspect of this disclosure relates to the use of a combination of Compound (A) as defined above, or a pharmaceutically acceptable salt thereof, and an antibody-drug conjugate for treating a cancer in a subject, wherein the antibody-drug conjugate comprising a maytansinoid is represented by the following structural formula: or a pharmaceutically acceptable salt thereof, wherein:
  • Ab is an antibody or an antigen-binding fragment thereof; and n represents an average number of maytansinoid compounds conjugated to a single Ab and is in a range of about 1 to about 10. In one embodiment, n is in a range of about 3 to about 4.
  • the antibody-drug conjugate or Ab specifically binds to a target selected from the extracellular domain of human receptor tyrosine kinase- like orphan receptor 1 (ROR1), human epidermal growth factor receptor 2 (HER2), folate receptor alpha (FRa), cadherin 6 (CDH6), sodium-dependent phosphate transporter NaPi2b, tissue factor (TF or also known as platelet tissue factor, coagulation factor III (F3)) and CD142), mesothelin (MSLN), mucin 16 (MUC16 or also known as ovarian cancer- related tumor marker CA125).
  • ROR1 human receptor tyrosine kinase- like orphan receptor 1
  • HER2 human epidermal growth factor receptor 2
  • FRa folate receptor alpha
  • CDH6 cadherin 6
  • NaPi2b sodium-dependent phosphate transporter NaPi2b
  • tissue factor TF or also known as platelet tissue factor, coagulation factor III (F3)
  • CD 166 protein tyrosine kinase 7
  • AXL receptor tyrosine kinase AXL
  • antigen CD 166 CD 166
  • ENPP3 ectonucleotide pyrophosphatase/phosphodiesterase family member 3
  • TIM-1 T-cell immunoglobulin and mucin domain 1
  • CD70 also known as CD27L
  • B7 homolog 3 B7-H3, also know n as CD276
  • B7 homolog 4 B7-H4
  • TROP-2 trophoblast cell surface antigen 2
  • BCMA B-cell maturation antigen
  • the antibody-drug conjugate comprises an antibody or an antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof or Ab comprises:
  • a heavy chain CDR1 comprising GYFMN (SEQ ID NO: 1), a heavy chain CDR2 compnsing RIHPYDGDTFYNQKFQG (SEQ ID NO:2) and a heavy chain CDR3 comprising YDGSRAMDY (SEQ ID NO:3);
  • the antibody-drug conjugate comprises an antibody or an antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof or Ab comprises:
  • the antibody-drug conjugate comprises an antibody or an antigen-binding fragment thereof and wherein the antibody or antigenbinding fragment thereof or Ab comprises a heavy chain variable domain comprising SEQ ID NO:7. and a light chain variable domain comprising SEQ ID NO:8 or SEQ ID NO:9.
  • the antibody-drug conjugate comprises an antibody or an antigen-binding fragment thereof and wherein the antibody or antigen-binding fragment thereof or Ab comprises a heavy chain variable domain consisting of SEQ ID NO:7, and a light chain variable domain consisting of SEQ ID NO:8 or SEQ ID NO:9.
  • the antibody-drug conjugate comprises an antibody or an antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof or Ab comprises a heavy chain comprising SEQ ID NOTO, and a light chain comprising SEQ ID NO: 11.
  • the antibody-drug conjugate comprises an antibody or an antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof or Ab comprises a heavy chain consisting of SEQ ID NO: 10. and a light chain consisting of SEQ ID NO: 11.
  • an antibody or antigen-binding fragment thereof has at least 90% sequence identity to an amino acid sequence selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9. SEQ ID NO: 10 and SEQ ID NO: 11.
  • an antibody or antigen-binding fragment thereof has at least 95% sequence identity to an amino acid sequence selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10 and SEQ ID NO: 11.
  • an antibody or antigen-binding fragment thereof has at least 98% sequence identity to an amino acid sequence selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10 and SEQ ID NO: 11.
  • an antibody or antigenbinding fragment thereof has an amino acid sequence selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3. SEQ ID NO: 4, SEQ ID NO: 5.
  • an antibody or antigen-binding fragment thereof can have an amino acid sequence selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10 and SEQ ID NO: 11. wherein amino acid sequence may be chemically modified with one or more functional groups.
  • the uses and methods of the present disclosure include uses and methods of treating a cancer selected from a brain cancer, a cervicocerebral cancer, an esophageal cancer, a thyroid cancer, a small cell cancer, a non-small cell cancer, a breast cancer, a lung cancer (e.g..
  • a stomach cancer a urothelial cancer, a gallbladder/bile duct cancer, a liver cancer, a pancreatic cancer, a colon cancer, a rectal cancer, a colorectal cancer, an ovarian cancer (e.g., epithelial ovarian cancer), a fallopian tube cancer, a primary peritoneal cancer, an uterine cancer, a choriocarcinoma, an uterus body cancer, an uterocervical cancer, a renal pelvis/ureter cancer, a bladder cancer, a prostate cancer, a penis cancer, a testicular cancer, a fetal cancer, Wilms' cancer, a skin cancer, malignant melanoma, a neuroblastoma, an osteosarcoma, an Ewing's tumor, a soft part sarcoma, an acute leukemia, a chronic lymphatic leukemia, a chronic myelocytic leukemia, a chronic myelocytic le
  • the cancer treated in the uses and methods of provided herein is a ‘‘platinum-sensitive cancer,” which as used herein and per Response Evaluation Criteria in Solid Tumors (RECIST) vl.l refers to a cancer or tumor that is sensitive to platinum-based chemotherapy (e.g., cisplatin, carboplatin, oxaliplatin and pharmaceutically acceptable salts thereof) that is defined as (1) > 30% decrease from baseline, confirmed at 4 weeks, (2) no > 20% increase over smallest sum observed or (3) no new lesions.
  • platinum-based chemotherapy e.g., cisplatin, carboplatin, oxaliplatin and pharmaceutically acceptable salts thereof
  • the cancer treated in the uses and methods of provided herein is a “platinum-resistant cancer.” which as used herein and per Response Evaluation Criteria in Solid Tumors (RECIST) vl. l refers to a cancer or tumor that may have previously responded to, but no longer responds, to platinum-based chemotherapy that is defined as (1) > 30% decrease from baseline or (2) no > 20% increase over smallest sum observed and no new lesions at 4 weeks.
  • the cancer acquires resistance, for example, via prior exposure to platinum-based therapy, either as monotherapy or in combination with other compounds (such as other chemotherapy, immune checkpoint inhibitors, etc.).
  • the cancer treated in the uses and methods of provided herein is a “platinum-refractory cancer,” which as used herein and per Response Evaluation Criteria in Solid Tumors (RECIST) vl. l refers to a cancer or tumor which never responded to platinum-based chemotherapy that is defined as (1) > 30% decrease from baseline or (2) no > 20% increase over smallest sum observed and no new lesions at 4 weeks.
  • the cancer is inherently resistant.
  • the subject with the cancer has received at least one prior systemic treatment regimens. In one embodiment, the subject has received one to three prior systemic treatment regimens.
  • Such first-line standard therapies include immunotherapy, such as an immune checkpoint inhibitor, alone or in combination with chemotherapy, such as platinum-based chemotherapy.
  • platinum-based chemotherapy include cisplatin, carboplatin and oxaliplatin (including pharmaceutically acceptable salts of any of the foregoing).
  • Non-limiting examples of immune checkpoint inhibitors include PD-1 inhibitors, PD-L1 inhibitors, CTLA-4 inhibitors and LAG-3 inhibitors (including pharmaceutically acceptable salts of any of the foregoing).
  • an immune checkpoint inhibitor may be bi- or multi-specific and may target at least two proteins, including, but not limited to. two proteins selected from PD-1, PD-L1. CTLA-4 and LAG-3.
  • Non-limiting examples of PD-1 inhibitors include retifanlimab, pucotenlimab, cadonilimab, serplulimab, nivolumab (relatimab), zimberelimab, penpulimab, dostarlimab (dostarlimab-gxly), prolgolimab, tislelizumab, camrelizumab, sintilimab, toripalimab, cemiplimab (cemiplimab-RWLC). pembrolizumab, nivolumab.
  • balstilimab finotonlimab, iparomlimab, ivonescimab, tuvonralimab/iparomlimab, cetrelimab, favezelimab/pembrolizumab, genolimzumab, nofazinlimab, pembrolizumab/hyaluronidase, pembrolizumab/quavonlimab, pembrolizumab/vibostolimab, pembrolizumab/quavonlimab, rilvegostomig. sasanlimab, spartalizumab. tebotelimab and volrustomig (including pharmaceutically acceptable salts of any of the foregoing).
  • Non-limiting examples of PD-L1 inhibitors include socazolimab, adebrelimab, sugemalimab, envafolimab, durvalumab, avelumab, atezolizumab, benmelstobart, tagitanlimab. bintrafusp alfa, erfonrilimab and retlirafusp alfa (including pharmaceutically acceptable salts of any of the foregoing).
  • CTLA-4 inhibitors include tremelimumab, cadonilimab, ipilimumab, tuvonralimab/paromlimab, erfonrilimab. gotistobart, pembrolizumab/quavonlimab, pembrolizumab/quavonlimab, quavonlimab and volrustomig (including pharmaceutically acceptable salts of any of the foregoing).
  • Non-limiting examples of LAG-3 inhibitors include nivolumab/relatlimab, bootszelimab/pembrolizumab, fianlimab, relatlimab, tebotelimab, eftilagimod alpha and favezelimab (including pharmaceutically acceptable salts of any of the foregoing).
  • the order of administration or use of the combination of Compound (A) and maytansinoid or an antibody-drug conjugate comprising maytansinoid (including pharmaceutically acceptable salts of any of the foregoing) described herein can vary.
  • Compound (A), or a pharmaceutically acceptable salt thereof, and a maytansinoid, or a pharmaceutically acceptable salt thereof, or an antibody-drug conjugate comprising a maytansinoid, or a pharmaceutically acceptable salt thereof are administered or used sequentially.
  • Compound (A), or a pharmaceutically acceptable salt thereof can be administered prior to a maytansinoid or an antibody-drug conjugate comprising a maytansinoid, or a pharmaceutically acceptable salt of any of the foregoing. In other embodiments, Compound (A), or a pharmaceutically acceptable salt thereof, can be administered subsequent to or after a maytansinoid or an antibody-drug conjugate comprising a maytansinoid, or a pharmaceutically acceptable salt of any of the foregoing.
  • Compound (A), or a pharmaceutically acceptable salt thereof can be administered concomitantly or concurrently with maytansinoid or an antibody-drug conjugate comprising maytansinoid, or a pharmaceutically acceptable salt of any of the foregoing.
  • Compound (A), or a pharmaceutically acceptable salt thereof is in use on an intermittent dosing schedule. In some embodiments, Compound (A), or a pharmaceutically acceptable salt thereof, is in use on an intermittent 5 days on, 2 days off dosing schedule.
  • the cancer treated in the uses and methods of provided herein may be further characterized by one or more biomarkers.
  • the cancer treated in the uses and methods of provided herein may be further characterized by the folate receptor alpha (FRa) status.
  • the cancer has a folate receptor alpha (FRa)-positive status.
  • the cancer has a folate receptor alpha (FRa)-high status.
  • the cancer has a folate receptor alpha (FRa)-medium status.
  • the cancer has a folate receptor alpha (FRa)- low status.
  • the cancer has a folate receptor alpha (FRa)-negative status.
  • the cancer treated in the uses and methods of provided herein may be further charactenzed by the Cyclin El status.
  • the cancer has a Cyclin El -positive status.
  • the cancer has a Cyclin El - high status.
  • the cancer has a Cyclin El-low status.
  • the cancer has a Cyclin El-negative status.
  • the folate receptor alpha (FRa) status and the Cyclin El status the respective receptor or protein levels, or rnRNA or transcript levels thereof, in a tumor sample obtained from a subject; and a H-score, an immunochemistry (IHC) staining intensity score (e.g, 1+. 2+, 3+) may be derived or calculated.
  • the expression of each protein is assessed using a 0 to 3+ intensity score by a trained and qualified observer with categorization of ambiguous cases confirmed by a pathologist and the percentage of tumor cells having an IHC 1+, 2+, or 3+ intensity staining score (i.e., score 1 and above, score 2 and above, score 3 and above) is obtained and used to determine protein expression level.
  • the cancer treated in the uses and methods of provided herein may be characterized by the presence of a TP53 mutation.
  • the term “antagonistic” means that the activity of the combination of compounds is less compared to the sum of the activities of the compounds in combination when the activity of each compound is determined individually (i.e., as a single compound).
  • the term “synergistic effect” means that the activity of the combination of compounds is greater than the sum of the individual activities of the compounds in the combination when the activity of each compound is determined individually.
  • the term “additive effect” means that the activity of the combination of compounds is about equal to the sum of the individual activities of the compounds in the combination when the activity of each compound is determined individually.
  • a potential advantage of utilizing a combination as described herein may be a reduction in the required amount(s) of the compound(s) that is effective in treating a disease condition disclosed herein compared to when a maytansinoid or an antibody-drug conjugate comprising a maytansinoid, or a pharmaceutically acceptable salt of any of the foregoing, is administered as a monotherapy.
  • the amount of a maytansinoid or an antibody-drug conjugate comprising maytansinoid, or a pharmaceutically acceptable salt of any of the foregoing, used in a combination described herein can be less compared to the amount of a maytansinoid or an antibody -drug conjugate comprising maytansinoid, or a pharmaceutically acceptable salt of any of the foregoing, needed to achieve the same reduction in a disease marker (for example, tumor size) when administered as a monotherapy.
  • a disease marker for example, tumor size
  • Another potential advantage of utilizing a combination as described herein is that the use of two or more compounds having different mechanisms of action can create a higher barrier to the development of resistance compared to when a maytansinoid or an antibody-drug conjugate comprising maytansinoid, or a pharmaceutically acceptable salt thereof, is administered as monotherapy. Additional advantages of utilizing a combination as described herein may include little to no cross resistance between the compounds of a combination described herein; different routes for elimination of the compounds of a combination described herein; and/or little to no overlapping toxi cities between the compounds of a combination described herein.
  • Compound (A), or a pharmaceutically acceptable salt thereof can be provided in a pharmaceutical composition.
  • a maytansinoid or an antibody-drug conjugate comprising maytansinoid can be provided in a pharmaceutical composition.
  • pharmaceutically acceptable salts of any of the foregoing can be provided in a pharmaceutical composition.
  • composition refers to a mixture of one or more compounds and/or salts disclosed herein with other chemical components, such as diluents, carriers and/or excipients.
  • the pharmaceutical composition facilitates administration of the compound to an organism.
  • Pharmaceutical compositions can also be obtained by reacting compounds with inorganic or organic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, and salicylic acid.
  • Pharmaceutical compositions will generally be tailored to the specific intended route of administration.
  • a “carrier” refers to a compound that facilitates the incorporation of a compound into cells or tissues.
  • DMSO dimethyl sulfoxide
  • a “diluent” refers to an ingredient in a pharmaceutical composition that lacks appreciable pharmacological activity but may be pharmaceutically necessary or desirable.
  • a diluent may be used to increase the bulk of a potent drug whose mass is too small for manufacture and/or administration. It may also be a liquid for the dissolution of a drug to be administered by injection, ingestion or inhalation.
  • a common form of diluent in the art is a buffered aqueous solution such as, without limitation, phosphate buffered saline that mimics the pH and isotonicity of human blood.
  • an “excipient” refers to an essentially inert substance that is added to a pharmaceutical composition to provide, without limitation, bulk, consistency, stability , binding ability, lubrication, disintegrating ability etc., to the composition.
  • stabilizers such as anti-oxidants and metal-chelating agents are excipients.
  • the pharmaceutical composition comprises an anti-oxidant and/or a metal-chelating agent.
  • a “diluent” is a type of excipient.
  • a maytansinoid or an antibody-drug conjugate comprising maytansinoid, along with pharmaceutically acceptable salts of any of the foregoing can be provided in a pharmaceutical composition that includes Compound (A), or a pharmaceutically acceptable salt thereof.
  • a maytansinoid or an antibody-drug conjugate comprising maytansinoid, along with pharmaceutically acceptable salts of any of the foregoing can be administered in a pharmaceutical composition that is separate from a pharmaceutical composition that includes Compound (A), or a pharmaceutically acceptable salt thereof.
  • compositions described herein can be administered to a human patient per se, or in pharmaceutical compositions where they are mixed with other active ingredients, as in combination therapy, or earners, diluents, excipients or combinations thereof. Proper formulation is dependent upon the route of administration chosen. Techniques for formulation and administration of the compounds described herein are known to those skilled in the art.
  • compositions disclosed herein may be manufactured in a manner that is itself known, e.g.. by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or tableting processes. Additionally, the active ingredients are contained in an amount effective to achieve its intended purpose. Many of the compounds used in the pharmaceutical combinations disclosed herein may be provided as salts with pharmaceutically compatible counterions. [0063] Multiple techniques of administering a compound, salt and/or composition exist in the art including, but not limited to.
  • Compound (A), or a pharmaceutically acceptable salt thereof can be administered orally.
  • Compound (A), or a pharmaceutically acceptable salt thereof can be provided to a subject by the same route of administration as a maytansinoid or an antibodydrug conjugate comprising maytansinoid, along with pharmaceutically acceptable salts thereof.
  • Compound (A), or a pharmaceutically acceptable salt thereof can be provided to a subject by a different route of administration as a maytansinoid or an antibody-drug conjugate comprising maytansinoid, along with pharmaceutically acceptable salts thereof.
  • the liposomes will be targeted to and taken up selectively by the organ. For example, intranasal or pulmonary delivery to target a respiratory disease or condition may be desirable.
  • compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient.
  • the pack may for example comprise metal or plastic foil, such as a blister pack.
  • the pack or dispenser device may be accompanied by instructions for administration.
  • the pack or dispenser may also be accompanied with a notice associated with the container in form prescribed by a governmental agency regulating the manufacture, use, or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the drug for human or veterinary administration. Such notice, for example, may be the labeling approved by the U.S. Food and Drug Administration for prescription drugs, or the approved product insert.
  • Compositions that can include a compound and/or salt described herein formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition. Uses and Methods of Treatment
  • a combination of compounds that includes an effective amount of Compound (A), or a pharmaceutically acceptable salt thereof, and an effective amount of a maytansinoid or an antibody-drug conjugate comprising maytansinoid, or a pharmaceutically acceptable salt of any of the foregoing, can be used to treat a cancer.
  • a subject can relapse or have reoccurrence of the cancer.
  • the terms “relapse” and “reoccurrence” are used in their normal sense as understood by those skilled in the art.
  • the cancer can be a recurrent cancer.
  • a “subject” refers to an animal that is the object of treatment, observation or experiment.
  • Animal includes cold- and warm-blooded vertebrates and invertebrates such as fish, shellfish, reptiles and, in particular, mammals.
  • “Mammal” includes, without limitation, mice, rats, rabbits, guinea pigs, dogs, cats, sheep, goats, cows, horses, primates, such as monkeys, chimpanzees, and apes, and, in particular, humans.
  • the subject can be human.
  • the subject can be a child and/or an infant.
  • the subject can be an adult.
  • treat do not necessarily mean total cure or abolition of the disease or condition. Any alleviation of any undesired signs or symptoms of the disease or condition, to any extent can be considered treatment and/or therapy. Furthermore, treatment may include acts that may worsen the subject’s overall feeling of well-being or appearance.
  • an effective amount of compound, salt or composition can be the amount needed to prevent, alleviate or ameliorate symptoms of the disease or condition, or prolong the survival of the subject being treated. This response may occur in a tissue, system, animal or human and includes alleviation of the signs or symptoms of the disease or condition being treated. Determination of an effective amount is well within the capability of those skilled in the art, in view of the disclosure provided herein.
  • the effective amount of the compounds disclosed herein required as a dose will depend on the route of administration, the type of animal, including human, being treated and the physical characteristics of the specific animal under consideration. The dose can be tailored to achieve a desired effect, but will depend on such factors as weight, diet, concurrent medication and other factors which those skilled in the medical arts will recognize.
  • an effective amount of a compound, or radiation is the amount that results in: (a) the reduction, alleviation or disappearance of one or more symptoms caused by the cancer, (b) the reduction of tumor size, (c) the elimination of the tumor, and/or (d) long-term disease stabilization (growth arrest) of the tumor.
  • the amount of compound, salt and/or composition required for use in treatment will vary not only with the particular compound or salt selected but also with the route of administration, the nature and/or symptoms of the disease or condition being treated and the age and condition of the patient and will be ultimately at the discretion of the attendant physician or clinician.
  • dosages may be calculated as the free base.
  • the useful in vivo dosage to be administered and the particular mode of administration will vary' depending upon the age, weight, the severity of the affliction, the mammalian species treated, the particular compounds employed and the specific use for which these compounds are employed.
  • the determination of effective dosage levels that is the dosage levels necessary to achieve the desired result, can be accomplished by one skilled in the art using routine methods, for example, human clinical trials, in vivo studies and in vitro studies.
  • useful dosages of Compounds (A) and a maytansinoid or an antibody-drug conjugate comprising maytansinoid, or pharmaceutically acceptable salts of the foregoing can be determined by 7 comparing their in vitro activity, and in vivo activity' in animal models. Such comparison can be done by comparison against an established drug, such as cisplatin and/or gemcitabine.
  • Dosage amount and interval may be adjusted individually to provide plasma levels of the active moiety which are sufficient to maintain the modulating effects, or minimal effective concentration (MEC).
  • MEC minimal effective concentration
  • the MEC will vary for each compound but can be estimated from in vivo and/or in vitro data. Dosages necessary to achieve the MEC will depend on individual characteristics and route of administration. However, HPLC assays or bioassays can be used to determine plasma concentrations. Dosage intervals can also be determined using MEC value.
  • Compositions should be administered using a regimen which maintains plasma levels above the MEC for 10-90% of the time, such as between 30-90% and between 50-90%. In cases of local administration or selective uptake, the effective local concentration of the drug may not be related to plasma concentration.
  • a dosing regimen may comprise an “intermittent’' dosing, during which one or more dosing parameters such as dosage amount and/or dosage interval are varied or changed.
  • an intermittent dosing phase may comprise a period of continuous administration (e.g., 6 days, 5 days, 4 days in a week) followed by a “rest” phase (e.g., 1 day, 2 days, 3 days in the same week) during which Compound (A) is not administered or is administered at a reduced dosage amount and/or less frequently.
  • a dosing regimen may further comprise one or more repeated cycles of intermittent dosing regimens.
  • the attending physician would know how to and when to terminate, interrupt or adjust administration due to toxicity or organ dysfunctions. Conversely, the attending physician would also know to adjust treatment to higher levels if the clinical response was not adequate (precluding toxicity).
  • the magnitude of an administrated dose in the management of the disorder of interest will vary with the severity of the disease or condition to be treated and to the route of administration. The severity of the disease or condition may, for example, be evaluated, in part, by standard prognostic evaluation methods. Further, the dose and perhaps dose frequency, will also vary according to the age, body weight and response of the individual patient. A program comparable to that discussed above may be used in veterinary medicine.
  • Compounds, conjugates, salts and compositions disclosed herein can be evaluated for efficacy and toxicity using known methods.
  • the toxicology of a particular compound, or of a subset of the compounds, sharing certain chemical moieties may be established by determining in vitro toxicity towards a cell line, such as a mammalian, such as human, cell line. The results of such studies are often predictive of toxicity in animals, such as mammals, or more specifically, humans.
  • the toxicity of particular compounds in an animal model such as mice, rats, rabbits, dogs or monkeys, may be determined using known methods.
  • the efficacy of a particular compound may be established using several recognized methods, such as in vitro methods, animal models, or human clinical trials. When selecting a model to determine efficacy, the skilled artisan can be guided by the state of the art to choose an appropriate model, dose, route of administration and/or regime.
  • Example 1 Compound (A) and DM4 or Mirvetuximab Soravtansine In Vitro Synergy and Increased In Vitro DNA Damage/Mitotic Arrest/ Apoptosis
  • OVCAR3 ovarian cancer cells (HGSOC, folate receptor alpha-positive, /PJj-mutated.
  • CCNE1 -amplified were cultured in RPMI 1640 medium (ATCC modification) (Gibco) supplemented with 20% FBS (Gibco), 10 pg/rnL insulin (Sigma), and 1% penicillin-streptomycin (Gibco).
  • OV-90 high-grade serous ovarian cancer cells (HGSOC, folate receptor alpha-positive, 7/Gj-mutated.
  • Cyclin El -low were cultured in 1 : 1 mixture of MCDB 105 (1.5 g/L sodium bicarbonate) (Cell Applications) and Medium 199 (2.2 g/L sodium bicarbonate) (Gibco) supplemented with 15% FBS (Gibco) and 1% penicillin-streptomycin (Gibco). Cells were maintained at 37 °C in an atmosphere containing 5% CO2.
  • OVCAR3 or OV-90 cells were seeded at optimal density in 96-well plates for evaluation of combination treatments on cell viability. Treatments were performed the following day with Compound (A) and DM4 (0-0.5 nM for OVCAR3, 0-1 nM for OV90) or mirvetuximab soravtansine (0-10 nM) as monotherapies or in a matrix combination format. Cell viability was then measured 7 days following treatment by CellTiter-Glo 2.0 assay. Synergies between Compound (A) and DM4 were then calculated using ZIP synergy score from SynergyFinder tool (http://www.synergy fmderplus.org/).
  • OVCAR3 cells were seeded at optimal density in 6 cm dishes for the evaluation of combination treatments on biomarker changes. Treatment doses were determined from combination CellTiter-Glo assays and treatments were performed the following day with Compound (A) (250 nM) and DM4 (0.25 nM) or mirvetuximab soravtansine (5 nM) as monotherapies or as combination therapy. After indicated time of drug exposure, cells were harvested, rinsed with PBS, lysed and sonicated in cold RIPA buffer (Sigma) containing protease and phosphatase inhibitors for 15 minutes, and centrifuged at 4 °C, 15,000 rpm for 15 minutes.
  • Compound (A) 250 nM
  • DM4 0.25 nM
  • mirvetuximab soravtansine 5 nM
  • Protein concentrations were measured using the Pierce BCA Protein Assay kit (Thermo Fisher). JESS plates were loaded and run according to the manufacturer’s instructions.
  • Primary antibodies anti-Cyclin El was purchased from Abeam, anti-GAPDH was purchased from Invitrogen, anti-phospho-H3, anti-yH2AX, anti-phospho-CDKl, anti-phsopho-Chkl, anti-cleaved caspase 3, anti-Weel, and anti-CDKl were purchased from Cell Signaling Technology.
  • FIGS. 1A and 1C Compound (A) in combination with DM4 (FIG. 1A) or mirvetuximab soravtansine (FIG. 1C) consistently showed significant synergy' in OVCAR3 and OV-90 cells, i.e., demonstrated a clear synergy' (ZIP synergy score > 10) at depicted dose ranges, with increased DNA damage, mitosis arrest, and apoptosis as indicated by yH2AX. phosphor-Histone H3, and cleaved caspase 3. respectively (see FIGS. IB and ID).
  • Example 2 Compound (A) and DM4 or Mirvetuximab Soravtansine Combinations Increased In Vitro Mitotic Arrest/Mitotic Defects
  • OVCAR3 high-grade serous ovarian cancer cells (HGSOC, folate receptor alpha-positive, 77 ⁇ 5j-mutated. CC7VE7-amplified) were cultured in RPMI 1640 medium (ATCC modification) (Gibco) supplemented with 20% FBS (Gibco), 10 pg/mL insulin (Sigma), and 1% penicillin-streptomycin (Gibco). Cells were maintained at 37 °C in an atmosphere containing 5% CO2.
  • OVCAR3 cells were seeded at optimal density in 12-well plates for evaluation of combination treatments on cell cycle progression.
  • the cells were treated the following day with Compound (A) (300 nM) and DM4 (0.25 nM) for 24 hours or Compound (A) (300 nM) and mirvetuximab soravtansine (5 nM) for 48 hours as monotherapies or as combination therapy.
  • Cells were then harvested, fixed, and permeabilized before Alexa Fluor 488 anti -Histone H3 Phospho (SerlO) (BioLegend) staining, Click-iT Plus EdU Alexa Fluor 647 (Thermo Fisher) detection, and DNA content staining with FxCycle Violet (Thermo Fisher).
  • Cell cycle progression was measured using Attune Nxt flow cytometer, analyzed using FlowJo, and plotted using GraphPad Prism.
  • FIGS. 2A (top panel) and 2B While Compound (A) and DM4 alone induced limited mitotic arrest as indicated by the percentage of cells with pHH3-positive staining of 7.4% and 7.77%, respectively, the combination treatment significantly increased mitotic arrest to 39.3% with decreased cell population in G1 phase.
  • Compound (A) in combination with mirvetuximab soravtansine increased mitotic arrest to 18.79%, compared to 7.86% and 0.96% of cells arrested in mitosis with Compound (A) and mirvetuximab soravtansine monotherapies, respectively.
  • OVCAR3 cells were cultured as described above.
  • OVCAR3 cells were seeded at optimal density in 96-well plates for evaluation of combination treatments on mitotic cells. Treatment was performed the following day with mirvetuximab soravtansine (5 nM) for 48 hours and Compound (A) (300 nM) for 24 hours as monotherapies or as combination therapy . Cells were then fixed and permeabilized before primary antibodies staining (anti-a-tubulin and anti-pHH3 antibodies) followed by secondary antibodies and DAPI staining. Images were captured using Operetta CLS high-content analysis system. Mitotic cells were determined by pHH3 positive staining and plotted using GraphPad Prism. Mitotic phenotypes were determined by a-tubulin and DAPI staining and plotted using GraphPad Prism.
  • FIGS. 3A and 3B Compound (A) in combination with mirvetuximab soravtansine increased mitotic arrest as indicated by the percentage of cells with pHH3-positive staining. While Compound (A) and mirvetuximab soravtansine alone induced mitotic defects, the combination further increased the number of cells with abnormal mitosis ⁇ see FIGS. 3C and 3D).
  • a-tubulin light grey indicates spindles. pHH3 (white) serves as a mitosis marker, and DAPI (dark grey) indicates chromosome.
  • OV-90 high-grade serous ovarian cancer/carcinoma (HGSOC, 77 J 53-mulated. Cyclin El -low, folate receptor alpha-low) tumor cell line was maintained in vitro as monolayer culture in 1 :1 mixture of MCDB 105 (1.5 g/L sodium bicarbonate) and Medium 199 (2.2 g/L sodium bicarbonate) supplemented with 15% heat inactivated fetal bovine serum at 37°C in an atmosphere of 5% CO2 in air.
  • the tumor cells were routinely sub-cultured before confluence by trypsin-EDTA treatment, not to exceed 4-5 passages.
  • the cells growing in an exponential growth phase were harvested and counted for tumor inoculation.
  • Each mouse was inoculated subcutaneously on the right flank with single cell suspension of tumor cells (1 x io 7 ) in 100 pL 1: 1 mixture of MCDB 105 (1.5 g/L sodium bicarbonate) and Medium 199 (2.2 g/L sodium bicarbonate) and Matrigel mixture (1 : 1 ratio) without serum for the tumor development.
  • the TVs were used for calculation of the tumor growth inhibition (TGI, an indicator of antitumor effectiveness) value using the formula: (1 - (Ta - To) I (Cd - Co)) x 100%.
  • Ta and Ca were the mean tumor volumes of the treated and control animals, and To and Co were the mean tumor volumes of the treated and control animals at the start of the experiment.
  • FIGS. 4A and 4B the combination therapy of Compound (A) and mirvetuximab soravtansine induced tumor growth inhibition or tumor regressions that were superior to their respective monotherapies, when the tumor volumes were measured at day 25.
  • the top line is vehicle
  • the bottom line with open circles is the combination therapy
  • the middle two lines are the monotherapies.
  • the set of bars closest to the y-axis are vehicle
  • the middle sets of bars are the monotherapies
  • the right most set of bars is the combination therapy.
  • the body weight measurements in FIG. 4C indicated minimal body weight changes throughout the study in this exemplary combination therapy. Typically, a body weight loss of greater than 15% indicates that the treatment regimen is not well-tolerated.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Est divulguée dans la présente invention l'utilisation d'une association du composé (A), ou d'un sel pharmaceutiquement acceptable de celui-ci, et d'un maytansinoïde, ou d'un conjugué anticorps-médicament comprenant un maytansinoïde (y compris des sels pharmaceutiquement acceptables) pour le traitement d'un cancer.
PCT/US2025/019738 2024-03-14 2025-03-13 Polythérapie par inhibiteur de wee1 Pending WO2025193930A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202463565372P 2024-03-14 2024-03-14
US63/565,372 2024-03-14
US202463641592P 2024-05-02 2024-05-02
US63/641,592 2024-05-02

Publications (1)

Publication Number Publication Date
WO2025193930A1 true WO2025193930A1 (fr) 2025-09-18

Family

ID=97064542

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2025/019738 Pending WO2025193930A1 (fr) 2024-03-14 2025-03-13 Polythérapie par inhibiteur de wee1

Country Status (1)

Country Link
WO (1) WO2025193930A1 (fr)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021127039A1 (fr) * 2019-12-20 2021-06-24 Recurium Ip Holdings, Llc Combinaisons
WO2021127044A1 (fr) * 2019-12-20 2021-06-24 Recurium Ip Holdings, Llc Associations
WO2021127047A1 (fr) * 2019-12-20 2021-06-24 Recurium Ip Holdings, Llc Associations
WO2021127045A1 (fr) * 2019-12-20 2021-06-24 Recurium Ip Holdings, Llc Associations
WO2021231653A1 (fr) * 2020-05-15 2021-11-18 Recurium Ip Holdings, Llc Monothérapies et polythérapies
WO2023064282A1 (fr) * 2021-10-13 2023-04-20 Recurium Ip Holdings, Llc Combinaisons d'inhibiteurs de wee 1 et d'anticorps anti-cd47
WO2023076485A1 (fr) * 2021-10-28 2023-05-04 Recurium Ip Holdings, Llc Polythérapies comprenant des inhibiteurs de wee1 et des inhibiteurs de la réponse à l'endommagement de l'adn (ddr)
WO2023114871A1 (fr) * 2021-12-15 2023-06-22 Recurium Ip Holdings, Llc Utilisation d'une polythérapie pour le traitement du cancer

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021127039A1 (fr) * 2019-12-20 2021-06-24 Recurium Ip Holdings, Llc Combinaisons
WO2021127044A1 (fr) * 2019-12-20 2021-06-24 Recurium Ip Holdings, Llc Associations
WO2021127047A1 (fr) * 2019-12-20 2021-06-24 Recurium Ip Holdings, Llc Associations
WO2021127045A1 (fr) * 2019-12-20 2021-06-24 Recurium Ip Holdings, Llc Associations
WO2021231653A1 (fr) * 2020-05-15 2021-11-18 Recurium Ip Holdings, Llc Monothérapies et polythérapies
WO2023064282A1 (fr) * 2021-10-13 2023-04-20 Recurium Ip Holdings, Llc Combinaisons d'inhibiteurs de wee 1 et d'anticorps anti-cd47
WO2023076485A1 (fr) * 2021-10-28 2023-05-04 Recurium Ip Holdings, Llc Polythérapies comprenant des inhibiteurs de wee1 et des inhibiteurs de la réponse à l'endommagement de l'adn (ddr)
WO2023114871A1 (fr) * 2021-12-15 2023-06-22 Recurium Ip Holdings, Llc Utilisation d'une polythérapie pour le traitement du cancer

Similar Documents

Publication Publication Date Title
ES2883297T3 (es) Anticuerpos de función doble específicos para PD-L1 glucosilado y métodos de uso de los mismos
CA3183867C (fr) Combinaison d’un conjugué anticorps-médicament et d’un inhibiteur d’atr
US20240252673A1 (en) Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
US12246025B2 (en) Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugate
US20250066507A1 (en) Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
JP7460608B2 (ja) 抗ｐｄ－１抗体と抗組織因子抗体－薬物コンジュゲートとの組み合わせを用いるがんの治療方法
WO2021260583A1 (fr) Association d'un conjugué anticorps-médicament et d'un inhibiteur de la dna-pk
US20220387485A1 (en) Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugate
US20230233540A1 (en) Combination of antibody-drug conjugate and cdk9 inhibitor
US20240076394A1 (en) Modulating the immune response using anti-cd30 antibody-drug conjugates
JP2021533090A (ja) 併用療法
WO2025193930A1 (fr) Polythérapie par inhibiteur de wee1
WO2025231223A1 (fr) Polythérapie par inhibiteur de wee1
US20250302982A1 (en) Methods of treating cancer with anti-tissue factor antibody-drug conjugates
TW202506188A (zh) Trop2耦合生物分子、醫藥組合物及方法
WO2025090760A1 (fr) Anticorps spécifiques de scube3 et procédés d'utilisation
EA046961B1 (ru) Способы лечения рака с помощью комбинации антитела к pd-1 и конъюгата антитела к тканевому фактору и лекарственного средства
EA046283B1 (ru) Способы лечения рака с помощью комбинации средства на основе платины и конъюгата антитела к тканевому фактору с лекарственным средством
HK40036176A (en) Modulating the immune response using antibody-drug conjugates

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 25772561

Country of ref document: EP

Kind code of ref document: A1